The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.
 
Yvonne Marie Mowery
Research Funding - Merck
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Medtronic
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Consulting or Advisory Role - Daiichi Sankyo; Eisai; GlaxoSmithKline; Ignyta; Lilly; Loxo; Merck; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Ignyta; Janssen
 
Brian E. Brigman
Consulting or Advisory Role - Plexxikon
Other Relationship - Musculoskeletal Transplant Foundation
 
Steven Attia
Research Funding - AB Science (Inst); Bayer (Inst); Bayer (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Epizyme (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Christian Frederick Meyer
Consulting or Advisory Role - Eisai; Janssen
Travel, Accommodations, Expenses - Lilly; Plexxikon
Other Relationship - UpToDate
 
Scott Schuetze
Consulting or Advisory Role - Daiichi Sankyo; EMD Serono; EMD Serono; Janssen Research & Development
Research Funding - AB Science (Inst); Adaptimmune (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Janssen Research & Development (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - Lilly
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - Lilly
 
Lee P. Hartner
No Relationships to Disclose
 
Mohammed M. Milhem
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Genentech/Roche; Novartis
 
Gabriel Tinoco
No Relationships to Disclose
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Andrew J. Wagner
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Denise K. Reinke
No Relationships to Disclose
 
David G. Kirsch
Stock and Other Ownership Interests - Lumicell; X-RAD Therapeutics
Consulting or Advisory Role - Lumicell
Research Funding - Lilly; Merck; X-RAD Therapeutics
Patents, Royalties, Other Intellectual Property - Patent on an imaging device licensed to Lumicell; Royalty on an imaging agent being commercialized by Lumicell
Other Relationship - SARC: Sarcoma Alliance for Research though Collaboration